Barrett's Esophagus: Diagnosis, Management, and Key Updates.
| Autor: | Chang K; Department of Internal Medicine, University of California, Riverside School of Medicine, 900 University Avenue, Riverside, CA 92521, USA., Jackson CS; Section of Gastroenterology, Loma Linda VA Healthcare System, 11201 Benton Street, 2A-38, Loma Linda, CA 92357, USA., Vega KJ; Division of Gastroenterology & Hepatology, Augusta University-Medical College of Georgia, 1120 15th Street, AD-2226, Augusta, GA 30912, USA. Electronic address: kvega@augusta.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Gastroenterology clinics of North America [Gastroenterol Clin North Am] 2021 Dec; Vol. 50 (4), pp. 751-768. Date of Electronic Publication: 2021 Oct 06. |
| DOI: | 10.1016/j.gtc.2021.08.009 |
| Abstrakt: | Barrett's esophagus (BE) is the precursor lesion for esophageal adenocarcinoma (EAC) development. Unfortunately, BE screening/surveillance has not provided the anticipated EAC reduction benefit. Noninvasive techniques are increasingly available or undergoing testing to screen for BE among those with/without known risk factors, and the use of artificial intelligence platforms to aid endoscopic screening and surveillance will likely become routine, minimizing missed cases or lesions. Management of high-grade dysplasia and intramucosal EAC is clear with endoscopic eradication therapy preferred to surgery. BE with low-grade dysplasia can be managed with removal of visible lesions combined with endoscopic eradication therapy or endoscopic surveillance at present. (Copyright © 2021 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|